Skip To Main Content
Katie Ewer on Muck Rack

Katie Ewer

As seen in: Nature, Fast Company, Frontiers, Ad Age, The Drum, The Lancet, Mumbrella, Infectious Diseases News, Grazia Magazine (UK), WARC and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Katie

Contact Katie, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

A randomised trial of malaria vaccine R21/Matrix-M™ with and without antimalarial drugs in Thai adults - npj Vaccines

|
By Katie Ewer, Fernando Ramos-Lopez, Arjen M. Dondorp, Adrian Hill, Lorenz von Seidlein
| Nature Verified
Abstract In preparation for mass vaccinations with R21/Matrix-M™ combined with mass administrations of dihydroartemisinin, piperaquine, and a single low dose primaquine we assessed the tolerability, safety, and potential interactions of this combination affecting immunogenicity or pharmacokinetics. 120 healthy Thai volunteers were randomised to receive either antimalarials combined with vaccinations (n = 50), vaccinations alone (n = 50), or antimalarials only (n = 20).
Open in Who Shared Issue with article?

High-resolution African HLA resource uncovers HLA-DRB1 expression effects underlying vaccine response - Nature Medicine

|
By Alexander J. Mentzer, Martin Pollard Verified, Deepti Gurdasani, Amanda Chong, Rasmus Nielsen, Nicolas Timpson, Katie Ewer, Nick Edwards, Katie Jeffery, Pandurangan Vijayanand, Björn Peters, Alessandro Sette, Sodiomon B Sirima, Shabir Madhi, Alison Elliott, Gil McVean
| Nature Verified
Abstract How human genetic variation contributes to vaccine effectiveness in infants is unclear, and data are limited on these relationships in populations with African ancestries.
Open in Who Shared Issue with article?

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial

|
By John Frater, Peter Medawar Building, Katie Ewer, Ane Ogbe
| The Lancet Verified
Summary Background Data on vaccine immunogenicity against SARS-CoV-2 are needed for the 40 million people globally living with HIV who might have less functional immunity and more associated comorbidities than the general population. We aimed to explore safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in people with HIV.
Open in Who Shared Issue with article?
See all 16 licensed articles (43 Total)